The 12-month price targets, analyzed by analysts, offer insights with an average target of $352.0, a high estimate of $425.00, and a low estimate of $314.00. This current average represents a 5.57% ...

In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector. Net Margin: United Therapeutics's net margin is below ...

The United States, in particular ... at the forefront of both innovation and implementation in the breast cancer therapeutics landscape. PharmiWeb.com is Europe's leading industry-sponsored portal for ...

United Therapeutics has partnered with Robinson ... is not a fan of the burgeoning electric vertical-takeoff-and-landing industry. At the heart of Smith’s many criticisms is what he describes ...

Some Republicans have bristled at the hefty cost of the bill, and Democrats could reject the funding for it over the school ...

The healthcare industry, an essential component of global well-being and economic resilience, is undergoing significant ...

As tariffs, HHS workforce cuts and the ouster of CBER Director Peter Marks threaten the “lifeblood” of the cell and gene ...

associate vice president of medical engagement and capabilities at United Therapeutics. “There are now more conferences, and the industry relies on them more to engage with thought leaders." ...

with more than 25 years of industry experience, and vice president of clinical R&D Mary Smith, who led the development and approval of United Therapeutics’ neuroblastoma drug Unituxin.

The action, filed on Monday, April 21, 2025, in the United States District Court for the Middle District of North Carolina, alleges that United Therapeutics infringed ... common in the pharmaceutical ...